21521830	142	Jelovac D	Recent progress in the diagnosis and treatment of ovarian cancer.	CA	2011	103
23703322	142	Montero J	p53 regulates a non-apoptotic death induced by ROS.	Cell death and differentiation	2013	31
17611497	207	Carpten JD	A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.	Nature	2007	373
18504432	207	Bleeker FE	AKT1(E17K) in human solid tumours.	Oncogene	2008	55
19491896	207	Shoji K	The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.	British journal of cancer	2009	51
21216929	207	Janku F	PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.	Molecular cancer therapeutics	2011	127
22261800	207	Shimizu T	The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.	Clinical cancer research 	2012	110
24440717	207	Janku F	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.	Cell reports	2014	50
1338904	324	Miyoshi Y	Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene.	Human molecular genetics	1992	175
1651174	324	Groden J	Identification and characterization of the familial adenomatous polyposis coli gene.	Cell	1991	447
10969779	324	Esteller M	Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer.	Cancer research	2000	106
21247378	324	Klampfer L	Cytokines, inflammation and colon cancer.	Current cancer drug targets	2011	44
9020077	581	Rampino N	Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.	Science	1997	216
11062132	581	Zhang L	Role of BAX in the apoptotic response to anticancer agents.	Science	2000	201
11875499	581	LeBlanc H	Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.	Nature medicine	2002	109
11381269	657	Howe JR	Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis.	Nature genetics	2001	150
21203531	657	Timmermann B	Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis.	PloS one	2010	58
9145676	672	Struewing JP	The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.	The New England journal of medicine	1997	316
10883018	672	Holschneider CH	Ovarian cancer: epidemiology, biology, and prognostic factors.	Seminars in surgical oncology	2000	105
11179017	672	Risch HA	Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.	American journal of human genetics	2001	166
22314128	672	Krepischi AC	Germline DNA copy number variation in familial and early-onset breast cancer.	Breast cancer research 	2012	31
24292448	672	Phelan CM	Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.	British journal of cancer	2014	23
16804544	673	Weisenberger DJ	CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.	Nature genetics	2006	534
17148775	673	Samowitz WS	Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer.	Journal of the National Cancer Institute	2006	105
18519771	673	French AJ	Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.	Clinical cancer research 	2008	71
18832519	673	Ogino S	CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.	Gut	2009	259
20587792	673	Limsui D	Cigarette smoking and colorectal cancer risk by molecularly defined subtypes.	Journal of the National Cancer Institute	2010	88
20635392	673	Tie J	Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.	International journal of cancer	2011	39
21285991	673	Yokota T	BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer.	British journal of cancer	2011	79
21456008	673	Tran B	Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.	Cancer	2011	92
21768580	673	Ladabaum U	Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.	Annals of internal medicine	2011	71
22012135	673	Capper D	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.	Acta neuropathologica	2012	40
22147942	673	Ogino S	Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.	Clinical cancer research 	2012	80
22180495	673	Yang H	Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.	Cancer research	2012	54
22228154	673	Kalady MF	BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.	Diseases of the colon and rectum	2012	38
22355009	673	Hong DS	BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.	Clinical cancer research 	2012	36
22393095	673	Popovici V	Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.	Journal of clinical oncology 	2012	47
22608338	673	Falchook GS	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.	Lancet	2012	179
22899730	673	Phipps AI	BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics.	Cancer epidemiology, biomarkers and prevention 	2012	40
23056577	673	Safaee Ardekani G	The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.	PloS one	2012	34
23800934	673	Nishihara R	Aspirin use and risk of colorectal cancer according to BRAF mutation status.	JAMA	2013	48
23852808	673	Roepman P	Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition.	International journal of cancer	2014	47
23878352	673	Lochhead P	Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.	Journal of the National Cancer Institute	2013	81
24737664	673	Yaeger R	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.	Cancer	2014	29
25139339	673	Venderbosch S	Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.	Clinical cancer research 	2014	23
25918280	673	Fakih MG	Metastatic colorectal cancer: current state and future directions.	Journal of clinical oncology 	2015	33
26038390	673	Campbell PT	Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype.	Cancer epidemiology, biomarkers and prevention 	2015	16
26287849	673	Hyman DM	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.	The New England journal of medicine	2015	128
26338525	673	Cremolini C	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.	The Lancet. Oncology	2015	39
26527776	673	André T	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.	Journal of clinical oncology 	2015	20
27022117	673	Stadler ZK	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.	Journal of clinical oncology 	2016	18
9521327	699	Cahill DP	Mutations of mitotic checkpoint genes in human cancers.	Nature	1998	323
25979631	999	van der Post RS	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.	Journal of medical genetics	2015	26
22637696	1021	Ziskin JL	In situ validation of an intestinal stem cell signature in colorectal cancer.	Gut	2013	28
23197571	1021	Leary RJ	Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing.	Science translational medicine	2012	115
22133722	1024	Roychowdhury S	Personalized oncology through integrative high-throughput sequencing: a pilot study.	Science translational medicine	2011	165
10430607	1026	Bunz F	Disruption of p53 in human cancer cells alters the responses to therapeutic agents.	The Journal of clinical investigation	1999	247
11309634	1026	Watanabe T	Molecular predictors of survival after adjuvant chemotherapy for colon cancer.	The New England journal of medicine	2001	174
20507599	1026	Baba Y	Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.	Molecular cancer	2010	50
21331045	1026	Elyada E	CKIα ablation highlights a critical role for p53 in invasiveness control.	Nature	2011	56
10811111	1029	Esteller M	Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.	Cancer research	2000	93
17065427	1029	Ogino S	CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.	The Journal of molecular diagnostics 	2006	134
18922929	1029	Barault L	Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.	Cancer research	2008	106
19825961	1029	Ogino S	Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.	Clinical cancer research 	2009	92
21509761	1029	Ahn JB	DNA methylation predicts recurrence from resected stage III proximal colon cancer.	Cancer	2011	47
23135763	1029	Canto MI	International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer.	Gut	2013	87
25479140	1029	Grant RC	Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.	Gastroenterology	2015	23
20664940	1045	Minoo P	Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles.	International journal of oncology	2010	51
24764661	1045	Kim JH	Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.	World journal of gastroenterology	2014	21
17060676	1084	Locker GY	ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.	Journal of clinical oncology 	2006	270
25851626	1084	Tie J	Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.	Annals of oncology 	2015	38
12781359	1111	Bartek J	Chk1 and Chk2 kinases in checkpoint control and cancer.	Cancer cell	2003	347
9294210	1499	Ilyas M	Beta-catenin mutations in cell lines established from human colorectal cancers.	Proceedings of the National Academy of Sciences of the United States of America	1997	118
11381089	1499	Gottardi CJ	E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner.	The Journal of cell biology	2001	150
12045208	1499	Albuquerque C	The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade.	Human molecular genetics	2002	98
15973414	1499	Batlle E	EphB receptor activity suppresses colorectal cancer progression.	Nature	2005	110
16023783	1499	Verras M	Roles and regulation of Wnt signaling and beta-catenin in prostate cancer.	Cancer letters	2006	72
21521850	1499	Morikawa T	Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer.	JAMA	2011	78
21531761	1499	Osada T	Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.	Cancer research	2011	54
22494971	1499	Jeong WJ	Ras stabilization through aberrant activation of Wnt/β-catenin signaling promotes intestinal tumorigenesis.	Science signaling	2012	32
23325582	1499	Peeters M	Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.	Clinical cancer research 	2013	56
23337059	1499	Wangefjord S	Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.	Diagnostic pathology	2013	27
2294591	1630	Fearon ER	Identification of a chromosome 18q gene that is altered in colorectal cancers.	Science	1990	263
16230360	1786	Lee BH	Procainamide is a specific inhibitor of DNA methyltransferase 1.	The Journal of biological chemistry	2005	69
25924068	1950	Drost J	Sequential cancer mutations in cultured human intestinal stem cells.	Nature	2015	71
15158434	1956	Roskoski R Jr	The ErbB/HER receptor protein-tyrosine kinases and cancer.	Biochemical and biophysical research communications	2004	70
15753357	1956	Shigematsu H	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.	Cancer research	2005	142
15863375	1956	Moroni M	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.	The Lancet. Oncology	2005	197
16890793	1956	Mendelsohn J	Epidermal growth factor receptor targeting in cancer.	Seminars in oncology	2006	150
17290067	1956	Sequist LV	Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.	Journal of clinical oncology 	2007	144
17308052	1956	Buck E	Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.	Molecular cancer therapeutics	2007	70
17664471	1956	Khambata-Ford S	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.	Journal of clinical oncology 	2007	291
18339877	1956	Jhawer M	PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.	Cancer research	2008	130
18794099	1956	Personeni N	Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.	Clinical cancer research 	2008	51
18802721	1956	van Krieken JH	KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.	Virchows Archiv 	2008	73
19188670	1956	Allegra CJ	American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.	Journal of clinical oncology 	2009	311
19483740	1956	Linardou H	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.	Nature reviews. Clinical oncology	2009	57
19536109	1956	Walther A	Genetic prognostic and predictive markers in colorectal cancer.	Nature reviews. Cancer	2009	170
19636327	1956	Normanno N	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.	Nature reviews. Clinical oncology	2009	107
19738166	1956	Siena S	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.	Journal of the National Cancer Institute	2009	144
19806185	1956	Sartore-Bianchi A	Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.	PloS one	2009	85
19826477	1956	Soh J	Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.	PloS one	2009	66
19884556	1956	Laurent-Puig P	Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.	Journal of clinical oncology 	2009	189
19942479	1956	Folprecht G	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.	The Lancet. Oncology	2010	131
20100958	1956	Khambata-Ford S	Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	63
20100961	1956	Bardelli A	Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.	Journal of clinical oncology 	2010	160
20103678	1956	Baldus SE	Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.	Clinical cancer research 	2010	109
20399983	1956	Tol J	Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.	Clinical therapeutics	2010	50
20431034	1956	Tsiatis AC	Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.	The Journal of molecular diagnostics 	2010	105
20864632	1956	Attolini CS	A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	47
20921461	1956	Roberts PJ	Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?	Journal of clinical oncology 	2010	77
20921462	1956	Peeters M	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2010	181
20921465	1956	Douillard JY	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.	Journal of clinical oncology 	2010	342
21163703	1956	De Roock W	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.	The Lancet. Oncology	2011	125
21200037	1956	Dahabreh IJ	Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.	Annals of internal medicine	2011	47
21502544	1956	Van Cutsem E	Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.	Journal of clinical oncology 	2011	350
21641636	1956	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	199
21646616	1956	Price TJ	Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.	Journal of clinical oncology 	2011	58
22270724	1956	Montagut C	Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.	Nature medicine	2012	100
22448344	1956	Corcoran RB	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.	Cancer discovery	2012	179
22722830	1956	Misale S	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.	Nature	2012	333
22722843	1956	Diaz LA Jr	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.	Nature	2012	379
23021375	1956	Berg M	EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.	Discovery medicine	2012	32
23136247	1956	Gasch C	Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.	Clinical chemistry	2013	55
23233388	1956	Mostert B	KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.	International journal of cancer	2013	30
23265711	1956	Licitra L	Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.	European journal of cancer	2013	27
23404247	1956	Valtorta E	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.	International journal of cancer	2013	34
23584090	1956	De Sousa E Melo F	Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions.	Nature medicine	2013	132
23852704	1956	Duffy MJ	Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.	International journal of cancer	2014	26
24098024	1956	Pichler M	miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.	Journal of clinical pathology	2014	26
24202392	1956	Chong CR	The quest to overcome resistance to EGFR-targeted therapies in cancer.	Nature medicine	2013	168
24269963	1956	Roskoski R Jr	The ErbB/HER family of protein-tyrosine kinases and cancer.	Pharmacological research	2014	122
24666267	1956	Therkildsen C	The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.	Acta oncologica	2014	56
24685132	1956	Sun C	Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.	Cell reports	2014	43
24687833	1956	Schwartzberg LS	PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.	Journal of clinical oncology 	2014	99
24919569	1956	Van Cutsem E	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.	Clinical cancer research 	2014	22
25057166	1956	Missiaglia E	Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.	Annals of oncology 	2014	38
25115304	1956	Sorich MJ	Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.	Annals of oncology 	2015	68
25164765	1956	Brannon AR	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.	Genome biology	2014	54
25248381	1956	Laurent-Puig P	Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.	Clinical cancer research 	2015	30
25593032	1956	Linnekamp JF	Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes.	Cancer research	2015	21
25605843	1956	Van Cutsem E	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.	Journal of clinical oncology 	2015	74
25623215	1956	Arena S	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.	Clinical cancer research 	2015	24
25628445	1956	Morelli MP	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.	Annals of oncology 	2015	22
25639985	1956	Mao C	Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.	Scientific reports	2015	19
25673558	1956	Pietrantonio F	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.	European journal of cancer	2015	37
25673644	1956	Ahronian LG	Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.	Cancer discovery	2015	46
25989278	1956	Rowland A	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.	British journal of cancer	2015	21
26030179	1956	Siravegna G	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.	Nature medicine	2015	58
26243863	1956	Kavuri SM	HER2 activating mutations are targets for colorectal cancer treatment.	Cancer discovery	2015	18
26318427	1956	Bronte G	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?	Oncotarget	2015	16
26358176	1956	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	25
26438111	1956	Allegra CJ	Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.	Journal of clinical oncology 	2016	31
26460303	1956	Kopetz S	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.	Journal of clinical oncology 	2015	41
26644315	1956	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	23
26690310	1956	Richman SD	HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.	The Journal of pathology	2016	11
26843189	1956	Arena S	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.	Science translational medicine	2016	11
27922044	1956	Punt CJ	From tumour heterogeneity to advances in precision treatment of colorectal cancer.	Nature reviews. Clinical oncology	2017	5
20609351	1978	She QB	4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.	Cancer cell	2010	135
23542178	1978	Ducker GS	Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.	Oncogene	2014	26
23589555	2064	Sleijfer S	Designing transformative clinical trials in the cancer genome era.	Journal of clinical oncology 	2013	35
8598045	2272	Ohta M	The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers.	Cell	1996	207
17599906	2475	Woo SY	PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.	The Journal of biological chemistry	2007	75
23549875	2475	Coffee EM	Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.	Clinical cancer research 	2013	28
8942985	2956	Acharya S	hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6.	Proceedings of the National Academy of Sciences of the United States of America	1996	142
10544223	2956	Lynch HT	Genetic susceptibility to non-polyposis colorectal cancer.	Journal of medical genetics	1999	131
11048711	2956	Lamers MH	The crystal structure of DNA mismatch repair protein MutS binding to a G x T mismatch.	Nature	2000	199
11257106	2956	Peltomäki P	Deficient DNA mismatch repair: a common etiologic factor for colon cancer.	Human molecular genetics	2001	94
15236168	2956	Hendriks YM	Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.	Gastroenterology	2004	82
15872200	2956	Hampel H	Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).	The New England journal of medicine	2005	244
16807412	2956	Barnetson RA	Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer.	The New England journal of medicine	2006	85
16885385	2956	Hampel H	Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.	Cancer research	2006	102
17003396	2956	Chen S	Prediction of germline mutations and cancer risk in the Lynch syndrome.	JAMA	2006	86
17327285	2956	Vasen HF	Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer).	Journal of medical genetics	2007	103
17531815	2956	Warren JJ	Structure of the human MutSalpha DNA lesion recognition complex.	Molecular cell	2007	141
17942460	2956	Imai K	Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics.	Carcinogenesis	2008	71
18556767	2956	Shia J	Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.	The Journal of molecular diagnostics 	2008	71
19622357	2956	Stoffel E	Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.	Gastroenterology	2009	77
20028993	2956	Baglietto L	Risks of Lynch syndrome cancers for MSH6 mutation carriers.	Journal of the National Cancer Institute	2010	73
20516444	2956	de la Chapelle A	Clinical relevance of microsatellite instability in colorectal cancer.	Journal of clinical oncology 	2010	44
21642682	2956	Bonadona V	Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.	JAMA	2011	114
22331944	2956	Win AK	Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.	Journal of clinical oncology 	2012	68
22355048	2956	Beamer LC	Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results.	Journal of clinical oncology 	2012	35
22658618	2956	Pritchard CC	ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing.	The Journal of molecular diagnostics 	2012	54
23091106	2956	Engel C	Risks of less common cancers in proven mutation carriers with lynch syndrome.	Journal of clinical oncology 	2012	32
25194673	2956	Haraldsdottir S	Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.	Gastroenterology	2014	35
25238946	2956	Lancaster JM	Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.	Gynecologic oncology	2015	24
25305506	2956	Sinicrope FA	Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.	Gastroenterology	2015	42
26031544	2956	Kawakami H	Microsatellite instability testing and its role in the management of colorectal cancer.	Current treatment options in oncology	2015	17
26657901	2956	Møller P	Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database.	Gut	2017	10
26880610	2956	Dudley JC	Microsatellite Instability as a Biomarker for PD-1 Blockade.	Clinical cancer research 	2016	28
27496117	2956	Provenzale D	Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.	Journal of the National Comprehensive Cancer Network 	2016	15
22763439	3082	Straussman R	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.	Nature	2012	413
15780936	3091	Koshiji M	HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression.	Molecular cell	2005	105
27322552	3091	Lu PH	Aqueous Oldenlandia diffusa extracts inhibits colorectal cancer cells via activating AMP-activated protein kinase signalings.	Oncotarget	2016	21
2547513	3265	Bos JL	ras oncogenes in human cancer: a review.	Cancer research	1989	956
22180306	3417	Borger DR	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.	The oncologist	2012	126
2438556	3845	Forrester K	Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.	Nature	1987	165
2453289	3845	Almoguera C	Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.	Cell	1988	407
3587348	3845	Bos JL	Prevalence of ras gene mutations in human colorectal cancers.	Nature	1987	293
9586664	3845	Andreyev HJ	Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.	Journal of the National Cancer Institute	1998	155
11097226	3845	Samowitz WS	Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.	Cancer epidemiology, biomarkers and prevention 	2000	99
11459867	3845	Adjei AA	Blocking oncogenic Ras signaling for cancer therapy.	Journal of the National Cancer Institute	2001	157
11531254	3845	Andreyev HJ	Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.	British journal of cancer	2001	201
12093899	3845	Smith G	Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.	Proceedings of the National Academy of Sciences of the United States of America	2002	98
15494427	3845	Yu JL	Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.	Blood	2005	108
15998951	3845	Ince WL	Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.	Journal of the National Cancer Institute	2005	69
16618717	3845	Lièvre A	KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.	Cancer research	2006	491
17101316	3845	Spring KJ	High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy.	Gastroenterology	2006	82
17375050	3845	Di Fiore F	Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.	British journal of cancer	2007	192
17998284	3845	De Roock W	KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.	Annals of oncology 	2008	206
18202412	3845	Lièvre A	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2008	336
18224685	3845	Barault L	Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.	International journal of cancer	2008	84
18316791	3845	Amado RG	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2008	728
18669866	3845	Perrone F	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.	Annals of oncology 	2009	112
18804418	3845	Linardou H	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.	The Lancet. Oncology	2008	184
18946061	3845	Karapetis CS	K-ras mutations and benefit from cetuximab in advanced colorectal cancer.	The New England journal of medicine	2008	797
19001320	3845	Di Nicolantonio F	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.	Journal of clinical oncology 	2008	416
19056857	3845	Santini D	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.	The oncologist	2008	57
19114683	3845	Bokemeyer C	Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.	Journal of clinical oncology 	2009	369
19124802	3845	Jimeno A	KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.	Journal of clinical oncology 	2009	58
19196673	3845	Tol J	Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.	The New England journal of medicine	2009	287
19237633	3845	Ogino S	PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.	Journal of clinical oncology 	2009	111
19339720	3845	Van Cutsem E	Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.	The New England journal of medicine	2009	786
19398573	3845	Loupakis F	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.	Journal of clinical oncology 	2009	123
19401449	3845	Wee S	PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.	Cancer research	2009	116
19603018	3845	Loupakis F	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.	British journal of cancer	2009	136
19603024	3845	Souglakos J	Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.	British journal of cancer	2009	76
19661383	3845	Yun J	Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.	Science	2009	210
19686742	3845	Nosho K	A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.	Gastroenterology	2009	53
19738126	3845	Jacobs B	Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2009	84
19884549	3845	Richman SD	KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.	Journal of clinical oncology 	2009	146
19908233	3845	Zlobec I	Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.	International journal of cancer	2010	58
19934290	3845	Ogino S	KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.	Clinical cancer research 	2009	62
20008640	3845	Roth AD	Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.	Journal of clinical oncology 	2010	282
20102720	3845	Goel A	Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.	Gastroenterology	2010	42
20413299	3845	Tol J	Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.	European journal of cancer	2010	61
20501503	3845	Fariña-Sarasqueta A	The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.	Annals of oncology 	2010	72
20570890	3845	Janakiraman M	Genomic and biological characterization of exon 4 KRAS mutations in human cancer.	Cancer research	2010	92
20603437	3845	Zhang W	A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.	Annals of oncology 	2011	37
20619739	3845	De Roock W	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.	The Lancet. Oncology	2010	475
20699365	3845	Halilovic E	PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.	Cancer research	2010	49
20736745	3845	Irahara N	NRAS mutations are rare in colorectal cancer.	Diagnostic molecular pathology 	2010	43
20927778	3845	Nosho K	Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.	The Journal of pathology	2010	104
20978259	3845	De Roock W	Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.	JAMA	2010	186
21228335	3845	Bokemeyer C	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.	Annals of oncology 	2011	163
21239505	3845	Tie J	KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.	Clinical cancer research 	2011	47
21305640	3845	Vaughn CP	Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.	Genes, chromosomes and cancer	2011	59
21364579	3845	Knijn N	KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.	British journal of cancer	2011	63
21383284	3845	Hutchins G	Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.	Journal of clinical oncology 	2011	125
21632860	3845	Molinari F	Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.	Clinical cancer research 	2011	56
21943101	3845	Makrodouli E	BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study.	Molecular cancer	2011	36
21985784	3845	Ebi H	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.	The Journal of clinical investigation	2011	63
22228631	3845	Spindler KL	Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.	Clinical cancer research 	2012	44
22247021	3845	Ihle NT	Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.	Journal of the National Cancer Institute	2012	83
22314188	3845	Pai RK	BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.	The American journal of surgical pathology	2012	35
22341439	3845	Singh A	TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.	Cell	2012	84
22446022	3845	Bokemeyer C	Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.	European journal of cancer	2012	123
22473155	3845	Tveit KM	Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.	Journal of clinical oncology 	2012	106
22474202	3845	Alberts SR	Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.	JAMA	2012	89
22481281	3845	Chang DT	Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.	Modern pathology 	2012	33
22613949	3845	Steckel M	Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.	Cell research	2012	45
22665543	3845	Vakiani E	Comparative genomic analysis of primary versus metastatic colorectal carcinomas.	Journal of clinical oncology 	2012	67
22734028	3845	Tejpar S	Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.	Journal of clinical oncology 	2012	98
22753589	3845	Imamura Y	Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.	Clinical cancer research 	2012	62
22798500	3845	Tian S	A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.	Gut	2013	26
23182985	3845	Peeters M	Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.	Journal of clinical oncology 	2013	63
23293113	3845	Tougeron D	Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.	Annals of oncology 	2013	29
23348904	3845	Rosty C	Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.	Modern pathology 	2013	47
23374602	3845	Pentheroudakis G	Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.	BMC cancer	2013	33
23419522	3845	Fabbri F	Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs.	Cancer letters	2013	47
23471846	3845	Heitzer E	Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.	Cancer research	2013	122
23511557	3845	Phipps AI	KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers.	British journal of cancer	2013	40
23660947	3845	Eklöf V	The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer.	British journal of cancer	2013	38
23725851	3845	Seymour MT	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.	The Lancet. Oncology	2013	65
23792451	3845	Ogino S	Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.	Oncogene	2014	38
24018645	3845	Vauthey JN	RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.	Annals of surgery	2013	29
24024839	3845	Douillard JY	Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.	The New England journal of medicine	2013	383
24042191	3845	Mouradov D	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.	The American journal of gastroenterology	2013	27
24043732	3845	Piessevaux H	Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2013	28
24385213	3845	Tahara T	Fusobacterium in colonic flora and molecular features of colorectal carcinoma.	Cancer research	2014	46
24645800	3845	Imperiale TF	Multitarget stool DNA testing for colorectal-cancer screening.	The New England journal of medicine	2014	144
24658074	3845	Thierry AR	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.	Nature medicine	2014	70
24687927	3845	Yoon HH	KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).	Clinical cancer research 	2014	22
25051912	3845	Zoratto F	Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis.	Tumour biology 	2014	35
25280443	3845	Phipps AI	Association between molecular subtypes of colorectal cancer and patient survival.	Gastroenterology	2015	75
25361982	3845	Klingbiel D	Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.	Annals of oncology 	2015	20
25706875	3845	Matano M	Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids.	Nature medicine	2015	74
25877855	3845	Tabernero J	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.	The Lancet. Oncology	2015	69
25937522	3845	Bokemeyer C	FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.	European journal of cancer	2015	24
26216840	3845	Carethers JM	Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.	Gastroenterology	2015	32
19098912	4072	Ligtenberg MJ	Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1.	Nature genetics	2009	137
8553070	4089	Hahn SA	DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.	Science	1996	423
15031030	4089	Gallione CJ	A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).	Lancet	2004	107
16135802	4089	Levy L	Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses.	Molecular and cellular biology	2005	90
24356649	4193	Zheng T	Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.	Nature communications	2013	34
10029064	4255	Esteller M	Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.	Cancer research	1999	212
16174854	4255	Shen L	MGMT promoter methylation and field defect in sporadic colorectal cancer.	Journal of the National Cancer Institute	2005	149
7661930	4292	Hamilton SR	The molecular basis of Turcot's syndrome.	The New England journal of medicine	1995	130
8044777	4292	Koi M	Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation.	Cancer research	1994	139
8128251	4292	Papadopoulos N	Mutation of a mutL homolog in hereditary colon cancer.	Science	1994	298
8145827	4292	Bronner CE	Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer.	Nature	1994	303
9354436	4292	Dietmaier W	Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression.	Cancer research	1997	129
9593786	4292	Aaltonen LA	Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease.	The New England journal of medicine	1998	185
9699680	4292	Cunningham JM	Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.	Cancer research	1998	142
11844828	4292	Lindor NM	Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors.	Journal of clinical oncology 	2002	153
15000146	4292	Grady WM	Genomic instability and colon cancer.	Cancer metastasis reviews	2004	75
15342696	4292	Domingo E	BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing.	Journal of medical genetics	2004	77
15855432	4292	Piñol V	Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.	JAMA	2005	99
16873062	4292	Kadyrov FA	Endonucleolytic function of MutLalpha in human mismatch repair.	Cell	2006	211
17301300	4292	Hitchins MP	Inheritance of a cancer-associated MLH1 germ-line epimutation.	The New England journal of medicine	2007	89
18398828	4292	Watson P	The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.	International journal of cancer	2008	95
19273709	4292	Bertagnolli MM	Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.	Journal of clinical oncology 	2009	103
20420947	4292	Boland CR	Microsatellite instability in colorectal cancer.	Gastroenterology	2010	270
22302899	4292	Sinicrope FA	Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications.	Clinical cancer research 	2012	50
23049789	4292	Antelo M	A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer.	PloS one	2012	36
23354017	4292	Rodríguez-Soler M	Risk of cancer in cases of suspected lynch syndrome without germline mutation.	Gastroenterology	2013	29
25224212	4292	Billingsley CC	Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.	Cancer	2015	17
18299561	4361	Barber TD	Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers.	Proceedings of the National Academy of Sciences of the United States of America	2008	127
7604264	4436	Drummond JT	Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells.	Science	1995	143
8252616	4436	Fishel R	The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.	Cell	1993	461
16951683	4436	Chan TL	Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer.	Nature genetics	2006	65
11818965	4595	Al-Tassan N	Inherited variants of MYH associated with somatic G:C--&amp;gt;T:A mutations in colorectal tumors.	Nature genetics	2002	265
12606733	4595	Sieber OM	Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH.	The New England journal of medicine	2003	141
16454848	4595	Galiatsatos P	Familial adenomatous polyposis.	The American journal of gastroenterology	2006	79
19822006	4595	Half E	Familial adenomatous polyposis.	Orphanet journal of rare diseases	2009	81
25645574	4595	Syngal S	ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.	The American journal of gastroenterology	2015	62
25980754	4595	Yurgelun MB	Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.	Gastroenterology	2015	18
15016963	5290	Samuels Y	High frequency of mutations of the PIK3CA gene in human cancers.	Science	2004	909
15254419	5290	Bachman KE	The PIK3CA gene is mutated with high frequency in human breast cancers.	Cancer biology and therapy	2004	179
15520168	5290	Campbell IG	Mutation of the PIK3CA gene in ovarian and breast cancer.	Cancer research	2004	221
15950905	5290	Samuels Y	Mutant PIK3CA promotes cell growth and invasion of human cancer cells.	Cancer cell	2005	287
16288007	5290	García-Rostán G	Mutation of the PIK3CA gene in anaplastic thyroid cancer.	Cancer research	2005	81
16357568	5290	Samuels Y	Oncogenic PI3K and its role in cancer.	Current opinion in oncology	2006	127
17314276	5290	Hollestelle A	Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.	Molecular cancer research 	2007	106
19223544	5290	Sartore-Bianchi A	PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.	Cancer research	2009	197
21829508	5290	Janku F	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.	PloS one	2011	60
22039088	5290	Mao C	PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.	Annals of oncology 	2012	51
22285706	5290	Sood A	PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.	Clinical colorectal cancer	2012	33
22357840	5290	Liao X	Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.	Clinical cancer research 	2012	88
23094721	5290	Liao X	Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.	The New England journal of medicine	2012	204
23532889	5290	Shigaki H	PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.	Clinical cancer research 	2013	28
23785428	5290	Rosty C	PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.	PloS one	2013	31
24062397	5290	Domingo E	Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.	Journal of clinical oncology 	2013	44
24218517	5290	Karapetis CS	PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.	Clinical cancer research 	2014	25
26392102	5290	Corcoran RB	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.	Journal of clinical oncology 	2015	48
27096951	5290	Elwood PC	Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies.	PloS one	2016	16
24501277	5424	Valle L	New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis.	Human molecular genetics	2014	33
26133394	5424	Bellido F	POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance.	Genetics in medicine 	2016	15
15960972	5728	Westbrook TF	A genetic screen for candidate tumor suppressors identifies REST.	Cell	2005	166
17218261	5728	Trotman LC	Ubiquitination regulates PTEN nuclear import and tumor suppression.	Cell	2007	205
17940504	5728	Frattini M	PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.	British journal of cancer	2007	135
20600018	5728	Heald B	Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.	Gastroenterology	2010	42
22252256	5728	Tan MH	Lifetime cancer risks in individuals with germline PTEN mutations.	Clinical cancer research 	2012	93
15247181	5928	Kambara T	BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum.	Gut	2004	144
16322293	5928	Benatti P	Microsatellite instability and colorectal cancer prognosis.	Clinical cancer research 	2005	66
17228023	5928	Kim GP	Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.	Journal of clinical oncology 	2007	83
17631130	5928	Jenkins MA	Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study.	Gastroenterology	2007	69
18395080	5928	Schwitalle Y	Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.	Gastroenterology	2008	56
20197478	5928	Dahlin AM	The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.	Clinical cancer research 	2010	75
24585723	5928	Goldstein J	Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).	Annals of oncology 	2014	30
9988270	6714	Irby RB	Activating SRC mutation in a subset of advanced human colon cancers.	Nature genetics	1999	107
16707622	6794	Hearle N	Frequency and spectrum of cancers in the Peutz-Jeghers syndrome.	Clinical cancer research 	2006	117
7761852	7040	Markowitz S	Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.	Science	1995	398
9822576	7040	Oft M	TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis.	Current biology 	1998	156
1905840	7157	Hollstein M	p53 mutations in human cancers.	Science	1991	1290
2144057	7157	Baker SJ	Suppression of human colorectal carcinoma cell growth by wild-type p53.	Science	1990	393
2253215	7157	Baker SJ	p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.	Cancer research	1990	157
2531845	7157	Nigro JM	Mutations in the p53 gene occur in diverse human tumour types.	Nature	1989	402
8030745	7157	Kim H	Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.	The American journal of pathology	1994	124
11859195	7157	Yu JL	Effect of p53 status on tumor response to antiangiogenic therapy.	Science	2002	86
16170357	7157	Bossi G	Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.	Oncogene	2006	68
16172461	7157	Russo A	The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.	Journal of clinical oncology 	2005	72
16951157	7157	Rodriguez J	Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers.	Cancer research	2006	82
19701195	7157	Fujita K	p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence.	Nature cell biology	2009	80
23649806	7157	Kleiblova P	Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.	The Journal of cell biology	2013	33
18813315	10000	Davies MA	A novel AKT3 mutation in melanoma tumours and cell lines.	British journal of cancer	2008	93
23104212	10178	Roth AD	Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.	Journal of the National Cancer Institute	2012	45
26314847	10178	Li Y	NEAT expression is associated with tumor recurrence and unfavorable prognosis in colorectal cancer.	Oncotarget	2015	24
25043054	10953	Zhang B	Proteogenomic characterization of human colon and rectal cancer.	Nature	2014	167
15155950	11122	Wang Z	Mutational analysis of the tyrosine phosphatome in colorectal cancers.	Science	2004	154
22195963	11186	Matallanas D	Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras.	Molecular cell	2011	43
24976383	11200	Ertych N	Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells.	Nature cell biology	2014	30
26483394	11200	Hu C	Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.	Cancer epidemiology, biomarkers and prevention 	2016	11
12438234	22882	Yuen ST	Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.	Cancer research	2002	95
18372904	22882	Haigis KM	Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.	Nature genetics	2008	193
20517689	26585	Bellam N	Tgf-beta signaling alterations and colon cancer.	Cancer treatment and research	2010	43
26060019	28990	Maby P	Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.	Cancer research	2015	15
27196573	29126	Masugi Y	Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.	Gut	2017	8
19856313	50943	Frey DM	High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients.	International journal of cancer	2010	80
25957691	54894	van de Wetering M	Prospective derivation of a living organoid biobank of colorectal cancer patients.	Cell	2015	99
14999283	55294	Rajagopalan H	Inactivation of hCDC4 can cause chromosomal instability.	Nature	2004	185
26912905	55294	Mlecnik B	The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.	Science translational medicine	2016	26
22810696	139285	Cancer Genome Atlas Network.	Comprehensive molecular characterization of human colon and rectal cancer.	Nature	2012	1543
